Microglial tau undergoes phosphorylation-independent modification after ischemia

Toshiki Uchihara1, Ayako Nakamura, Tetsuaki Arai

  • 1Department of Neuropathology, Tokyo Metropolitan Institute for Neuroscience, 2-6 Musashi-dai, Fuchu, Tokyo 183-8526, Japan. uchihara@tmin.ac.jp

Glia
|January 20, 2004
PubMed

Insights

The tau2 antibody detects pathological tau in Alzheimer's neurofibrillary tangles (NFTs) and microglia near ischemic areas. Triton X-100 (TX) disrupts tau2 binding in microglia, suggesting a reversible conformational change in tau after ischemia.

Area of Science:

  • Neuroscience
  • Immunohistochemistry
  • Biochemistry

Background:

  • Neurofibrillary tangles (NFTs) are hallmarks of Alzheimer's disease.
  • Microglia activation is observed around ischemic foci in the brain.
  • Tau protein is a key component of NFTs and can be modified in neurological conditions.

Purpose of the Study:

  • To investigate the nature of tau2 immunoreactivity in microglia around ischemic foci.
  • To determine if tau2 immunoreactivity in microglia is related to tau hyperphosphorylation.
  • To compare the conformational state of tau in microglia and NFTs.

Main Methods:

  • Immunohistochemistry using tau2 antibody on formalin-fixed, paraffin-embedded brain sections.
  • Western blot analysis of brain homogenates to detect tau2-immunoreactive bands.
  • Treatment with polyethyleneglycol-p-isooctylphenyl ether (Triton X-100; TX) to assess antibody binding and tau conformation.

Main Results:

  • Tau2 antibody labeled NFTs and microglia around ischemic foci.
  • Triton X-100 (TX) abolished tau2 immunoreactivity in microglia but not NFTs.
  • Tau2-immunoreactive bands in microglia were found in the Tris-soluble fraction and were not due to hyperphosphorylation.
  • TX disrupted tau2 binding in microglia, suggesting a reversible conformational change in tau after ischemia.
  • NFT-associated tau showed relative resistance to TX, indicating conformational differences.

Conclusions:

  • Tau modification after ischemia leads to a conformational change affecting tau2 binding in microglia.
  • The tau2 epitope in microglia exhibits susceptibility to TX, differing from its state in NFTs.
  • This conformational difference may be relevant for understanding tau pathology in ischemic conditions and neurodegenerative diseases.

Related Concept Videos

Phosphorylation01:02

Phosphorylation

The addition or removal of phosphate groups from proteins is the most common chemical modification that regulates cellular processes. These modifications can affect the structure, activity, stability, and localization of proteins within cells as well as their interactions with other proteins.
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...